SciClone Provides Initial 2013 Financial Guidance

SciClone Provides Initial 2013 Financial Guidance 
FOSTER CITY, CA -- (Marketwire) -- 01/07/13 --  SciClone
Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced its anticipated
2013 initial revenue, earnings per share (EPS) and year-end cash
guidance, and 2012 year-end cash position, as follows:  

--  The Company anticipates 2013 sales revenue of $150 million - $155
--  The Company expects 2013 non-GAAP EPS of $0.66 - $0.72 per share.
    SciClone's non-GAAP EPS excludes employee stock-based compensation
    from GAAP EPS.
--  The Company anticipates 2013 year-end cash and investments balances to
    be greater than $105 million excluding any impacts on cash balances
    associated with the Company's acquisition of new products, ongoing
    stock repurchase program and any other unbudgeted one-time cash
--  The Company expects cash and investments balances to be approximately
    $87 million (unaudited) at December 31, 2012. Excluding the cash
    impact of fourth quarter 2012 repurchases of common stock from the
    Company's share repurchase program, cash and investments would have
    been approximately $93 million (unaudited). Excluding the cash impact
    of the full-year 2012 repurchases of common stock from the Company's
    share repurchase program, cash and investments would have been
    approximately $112 million (unaudited).

"During the second half of 2012, we took important steps to strengthen
our on-going business and improve our future financial performance,
including recruiting high level executives with multinational
pharmaceutical management experience into the China organization and
significantly enhancing our sales and marketing strategies to
increase demand and expand market penetration and growth for
ZADAXIN(R) and our other products," commented Friedhelm Blobel,
Ph.D., President and Chief Executive Officer. "We believe that
implementation of these strategies will begin to positively affect
sales growth over the next several quarters, and position SciClone to
regain growth momentum as 2013 progresses."  
SciClone expects to report its complete fourth quarter and full-year
2012 financial results in early March 2013. 
About SciClone  
SciClone Pharmaceuticals is a US-based, China-focused specialty
pharmaceutical company with a product portfolio of therapies for
oncology, infectious diseases and cardiovascular, urological,
respiratory, and central nervous system disorders. SciClone's
ZADAXIN(R) (thymalfasin) is approved in over 30 countries and may be
used for the treatment of hepatitis B (HBV), hepatitis C (HCV) and
certain cancers, and as a vaccine adjuvant, according to the local
regulatory approvals. Besides ZADAXIN, SciClone markets about 14
mostly partnered products in China, including Depakine(R), the most
widely prescribed broad-spectrum anti-convulsant in China;
Tritace(R), an ACE inhibitor for the treatment of hypertension;
Stilnox(R), a fast-acting hypnotic for the short-term treatment of
insomnia (marketed as Ambien(R) in the US); and Aggrastat(R), a
recently-launched interventional cardiology product. SciClone is also
pursuing the registration of several other therapeutic products in
China. SciClone is headquartered in Foster City, California. For
additional information, please visit  
Forward-Looking Statements  
This press release contains forward-looking statements regarding
expected financial results and expectations. Readers are urged to
consider statements that include the words "may," "will," "would,"
"could," "should," "might," "believes," "estimates," "projects,"
"potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal," "unaudited,"
"approximately" or the negative of those words or other comparable
words to be uncertain and forward-looking. These statements are
subject to risks and uncertainties that are difficult to predict and
actual outcomes may differ materially. These include risks and
uncertainties relating to: changes in results that may occur in
completing the close of SciClone's consolidated financial statements
for fiscal year 2012 and completing the audit of SciClone's
consolidated financial statements for fiscal year 2012; the course,
cost and outcome of regulatory matters; the Company's ability to
execute on its goals in China and on its objectives for revenue in
fiscal 2013; the challenges presented by integrating an acquired
business into existing operations; the variability in earnings on a
GAAP basis that may result from non-cash charges related to the
NovaMed acquisition; the dependence on third-party license, promotion
or distribution agreements including the need to renew such
agreements; operating an international business; the clinical trial
process, including the regulatory approval and the process of
initiating trials at, and enrolling patients at, clinical sites; the
effect of changes in its practices and policies related to the
Company's compliance programs and SciClone's ability to attract and
retain key personnel. SciClone cannot predict the timing or outcome
of the SEC and DOJ investigations, or of the level of its efforts
required to cooperate with those investigations, however the Company
has incurred substantial expenses in connection with the
investigations and related litigation and expects to incur additional
expense and the investigations could result in fines and further
changes in its internal control or other remediation measures that
could adversely affect its business. Please also refer to other risks
and uncertainties described in SciClone's filings with the SEC. All
forward-looking statements are based on information currently
available to SciClone and SciClone assumes no obligation to update
any such forward-looking statements. 
Ambien, Depakine, Stilnox and Tritace are registered trademarks of
Sanofi and/or its affiliates. 
Aggrastat is a registered trademark of Medicure International Inc. in
the United States, and Iroko Cardio LLC in numerous other countries. 
SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals
design, the SciClone logo and ZADAXIN are registered trademarks of
SciClone Pharmaceuticals, Inc. in the United States and numerous
other countries. 
Corporate Contacts 
Gary Titus
Chief Financial Officer
Jane Green 
Press spacebar to pause and continue. Press esc to stop.